Since JAK2 mutations and dysregulated JAK-STAT signaling often contribute to leukemia cell survival, the use of JAK2 inhibitors in combination with conventional chemotherapy can sensitize leukemia cells to chemotherapeutic agents. This evidence concerns the gene JAK2 and leukemia.